Form 4: 10x Genomics Director Kimberly Popovits Granted Over 15,000 Restricted Stock Units

Kimberly J. Popovits, a Director at 10x Genomics, Inc. (TXG), was granted 15,357 restricted stock units (RSUs) on June 3, 2025, increasing her beneficial ownership to 28,616 shares.

Summary

• Kimberly J. Popovits, a Director of 10x Genomics, Inc. (TXG), acquired 15,357 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 3, 2025.
• The acquisition price for these RSUs was $0 per share, which is typical for equity grants.
• Following this transaction, Ms. Popovits beneficially owns a total of 28,616 shares of 10x Genomics Class A Common Stock.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs are scheduled to vest quarterly, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025, contingent upon Ms. Popovits's continued service as a director.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive event, as it aligns the director's financial interests with the long-term performance of the company and its shareholders, indicating continued commitment.

Positives

• The grant of 15,357 Restricted Stock Units (RSUs) to Director Kimberly J. Popovits aligns her financial interests with the long-term performance and shareholder value of 10x Genomics.
• An increase in beneficial ownership for a key director demonstrates continued commitment and confidence in the company's future.

Risks

• The vesting of the granted Restricted Stock Units (RSUs) is contingent upon the Reporting Person's continued service as a director through each vesting date.

Future Outlook

The 15,357 Restricted Stock Units (RSUs) are scheduled to vest quarterly, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025, provided the Reporting Person continues as a service provider.

Industry Context

This transaction represents a standard form of equity compensation for directors in publicly traded companies, aiming to align their long-term interests with those of shareholders. Such grants are common across various industries, including biotechnology and life sciences tools, where attracting and retaining experienced board members is crucial.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) is a common practice for compensating non-employee directors in the biotechnology and life sciences tools industry, similar to compensation structures observed at peer companies like Illumina (ILMN) or Pacific Biosciences (PACB).
• The specific size of the grant, 15,357 RSUs, is consistent with typical director compensation packages, which vary based on company size, market capitalization, and specific board responsibilities, but generally aim to provide competitive equity incentives.

Stakeholder Impact

• Shareholders: The grant of equity compensation to a director aligns their financial interests with the long-term performance of the company, potentially leading to more shareholder-friendly decisions and increased confidence in governance.

Next Steps

• Continued vesting of the 15,357 Restricted Stock Units (RSUs) on a quarterly basis, commencing from May 21, 2025, subject to Kimberly J. Popovits's continued service as a director.

Key Dates

Recommendation

Keywords

10x Genomics, TXG, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Kimberly Popovits